Commercial, Potential and Dichotomies of Cannabidiol

Q: What factors make HempMeds Mexico the ideal company for the commercialization of cannabidiol (CBD) products in Mexico?

A: HempMeds became the first company in Mexico to be approved by COFEPRIS to import CBD oil for patients with a clinical diagnosis of refractory epilepsy, among other conditions. We are a leading company in the US in the field of non-psychoactive cannabinoids like CBD and all our products are derived from legal industrial hemp crops in Europe and other countries.

Q: What difficulties has HempMeds faced in the introduction of a product in Mexico that public opinion has always associated with organized crime?

A: Misinformation has been the biggest problem because people do not differentiate cannabinoids from marijuana. We do not work with the psychoactive version of cannabis, which contains THC. In 2017, the WHO declared CBD as a non-psychotropic substance because it does not generate addiction.

Q: What is the true potential of CBD for the Mexican health industry?

A: HempMeds sees a big opportunity to use cannabinoids for balancing physiological functions related to the endocannabinoid system found in the human body in receptors such as CB1 and CB2. Mexico needs to invest more in R&D studies regarding the use of CDBs in therapeutic treatments and to expand the possibility of using substances derived from cannabis for research. Synthetic cannabinoids in the market have proved to have a positive effect, so that botanical cannabinoids combined with other drugs could generate a greater benefit.

Q: What advice would you give to doctors who have not changed their opinion about the use of CBD products?

A: This year, we have had more acceptance, but there is still confusion in the health industry. We are changing the mentality about CBDs and their therapeutic properties with professionalism and information. We hope that in the future non-psychotropic cannabinoids can be considered like any other supplement for human health. Research has shown a positive effect in the treatment of neurological diseases such as Alzheimer’s, which is why the health industry must press for more research into its medicinal properties. In Mexico, the industry has the advantage of being highly regulated in both therapeutic and industrial uses. The homologation of the national industry with international standards will encourage the importation of more products to Mexico that are derived from non-psychotropic cannabinoids.

Q: What alliances or partnerships is HempMeds looking for to consolidate its position in the Mexican market?

A: We are open to commercial partnerships oriented to product development with companies that are already in this branch and have experience in the pharmaceutical or food supplements segments. HempMeds Mexico seeks potential partners that share similar expectations in the growth and development of the hemp industry based on rigorous quality processes.

Q: How does HempMeds achieve cost-effective efficiency in its products?

A: All our products with CBD have a Triple Lab Testing process to guarantee quality and purity, from its crops to the finished product. The international parameters that we use in the industry help us to standardize the manufacturing process and the concentration of the doses; this makes HempMeds Mexico a very different company.

Q: What are the three main goals for HempMeds in the coming years?

A: First, we want to consolidate as the leading company of cannabinoids in Mexico. Later, we want to bring the full HempMeds’ stock to the country and to develop our products here for export. We think Mexico has favorable conditions and regulations to develop the full cycle of production for CBDs.